Publications by authors named "Laura Bernal-Masferrer"
Article Synopsis
- - This review explores various immunotherapeutic treatments for actinic keratoses (AKs), which are skin lesions caused by UV exposure, highlighting the immune-modulating effects of certain drugs like imiquimod and diclofenac.
- - It discusses the effectiveness of treatments such as 5-fluorouracil and photodynamic therapy in healthy individuals, noting that their effectiveness is reduced in patients with weakened immune systems, like solid organ transplant recipients.
- - The analysis emphasizes the potential of cryoimmunotherapy and introduces newer immunotherapies like resimiquimod and anti-PD1, but stresses that further research is needed to standardize their application.
Biologic treatments are increasingly being used in the management of moderate to severe plaque psoriasis (PSO). Risankizumab (RZB) is a humanized monoclonal antibody that specifically blocks the p19 subunit of interleukin 23, which in turn regulates the activation, differentiation, and survival of Th17. RZB has proved their efficacy and their safety compared to anti-TNF.
View Article and Find Full Text PDFMethyl aminolevulinate daylight photodynamic therapy (MAL DL-PDT) is highly efficacious for the treatment of nonhyperkeratotic actinic keratosis (AK), even when partially performed at home. To evaluate the long-term effectiveness, safety, and patient-reported outcomes of MAL DL-PDT performed completely by the patient in real life conditions. An open prospective study was conducted in Spain among patients diagnosed with at least five AK lesions on the face or the scalp.
View Article and Find Full Text PDF